We are thrilled to share the exciting news that Ms. Jennifer Che, our President and Managing Director, has been once again recognized on the IAM Strategy 300: The World's Leading IP Strategists of the year for 2025.


The IAM Strategy 300 is a guide to the pioneers in the industry. It recognizes individuals who are “leading the way in developing and implementing strategies that maximize the value of IP portfolios.” Individuals are nominated by the community, and only those identified by market sources for their “exceptional skill sets and profound insights into patent matters” are featured in the IAM Strategy 300. Jennifer's inclusion on this list underscores her outstanding credentials and unique strengths.


With a robust 20-year career as a scientist, patent attorney, and executive, Jennifer has helped numerous companies, institutions, inventors, and start-ups devise effective global intellectual property (IP) strategies. She excels at crafting integrated IP solutions that involve technical, regulatory, and long-range business needs. Jennifer's extensive experience in the U.S. and Greater China gives her a distinctive strategic eye for navigating complex cross-border IP challenges.


Jennifer is a highly regarded speaker and regularly gives talks in Hong Kong, Mainland China, the US, and around the world. She is also the founder and a frequent author of the blog chinapatentstrategy.com.
Please join us in congratulating Jennifer on this well-deserved recognition. Her expertise and dedication to her work make her an invaluable asset to our team and our clients.

我們過去活動

Recommended Insights

China’s Newest Examination Guidelines: Post-Filing Supplemental Data for Compounds (Part I)

2021年4月28日
Post-filing data in China has been a constant issue for many patent practitioners around the world. Examiners seem to require it often, and yet the rules regarding when it is acceptable have seemed much stricter than other jurisdictions worldwide. In fact, we tried to summarize the latest state of the law in an earlier blog […]

First ever Invalidation decision on an RNAi Invention patent in China

2023年12月4日
Decision on Examination of Request for Invalidation (No. 58530) In one of China’s Top 10 Patent Re-examination / Invalidation cases of 2022, an invalidation decision on a patent claiming Hepatitis B Virus (HBV) RNAi compositions (No. 58530) by the Patent Re-examination Board (the “Board”) sheds light on the standard for post filing data for rejections […]

CNIPA further clarifies how it counts “delays” when calculating Patent Term Adjustment (PTA) in the new Draft Examination Guidelines and how it affects international applicants

2023年4月12日
At the end of October 2022, the China National Intellectual Property Administration (CNIPA) released a new draft amendment of the Patent Examination Guidelines1 (hereinafter referred to as the “New Draft”) to the new Chinese Patent Law that came into effect in 2021. We highlight two key amendments below. 1. The starting date for calculating PTA […]

Miss the 12-month Filing Deadline? China Finally Allows Patent Applicants to Restore, Add, or Correct a Priority Claim

2024年4月15日
Three major 'remedial’ systems taken from the PCT Regulations have been introduced in the third revision of the Implementation Regulations of the Chinese Patent Law in 2023 (hereinafter referred to as the "Implementation Regulations"). We previously discussed one of these remedial systems, Incorporation by Reference based on Rule 45 of the Implementation Regulations, which allows […]
Top crossarrow-right